Recent Updates — AURX

Nuo Therapeutics received the full $325,000 second funding commitment on October 6, 2026, bringing total borrowings to $2 million. The company issued secured promissory notes bearing 12% annual interest due December 31, 2028, with interest payable in warrants. Warrants were issued to assuming lenders for the assigned portion of the commitment.

Nuo Therapeutics reported second quarter 2026 total revenues of approximately $1.77 million, a year-over-year increase exceeding 150%, with product sales reaching $1.69 million. The company posted a net loss of $277,601, an improvement from the prior year's loss of $649,689. Nuo also disclosed an amended loan agreement providing interim funding of $675,000, with $325,000 remaining available under total commitments of $2 million. The firm operates in the medical device industry, developing and marketing regenerative therapies for chronic wound care.